New oral formulation for the Treatment of Community-Acquired Lower Respiratory Tract Infections | CMAC

New oral formulation for the Treatment of Community-Acquired Lower Respiratory Tract Infections

Clinical Microbiology and Antimicrobial Chemotherapy. 2006; 8(4):350-358

​ Sinopalnikov A.I., Romanovskih A.G.
azithromycin antimicrobial activity pharmacokinetics lower respiratory tract infections review
Section
Antimicrobials
Type
Journal article
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2006; 8(4):350-358

Abstract

Azithromycin is one of the most commonly used macrolides in the treatment of respiratory tract infections. Azithromycin is a popular antimicrobial due to a number of its unique pharmacokinetic and pharmacodynamic properties. This review describes the new oral azithromycin formulation. Characteristics of the novel formulation of azithromycin are higher dose strength in combination with slow release of antibiotic, that allows to use azithromycin as a single-dose therapy. Controlled clinical trials showed that efficacy and safety of single-dose therapy with azitromycin was comparable to those of standard antimicrobial treatment regimens.

  • 1. McCaig L.F., Besser R.E., Hughes J.M. Antimicrobial drug prescription in ambulatory care settings, United States, 1992-2000. Emerg Infect Dis 2003; 9:432-7.
  • 2. http://student.ccbcmd.edu/courses/bio141/lecguide/unit4/genetics/protsyn/translation/macresr_illus.html.
  • 3. Drew R.H., Gallis H.A. Azithromycin – spectrum of activity, pharmacokinetics and clinical application. Pharmacother 1992; 12:161-73.
  • 4. Odenholt-Tornqvist I., Lowdin E., Cars O. Postantibiotic effects and postantibiotic sub-MIC effects of roxithromycin, clarithromycin, and azithromycin on respiratory tract pathogens. Antimicrob Agents Chemother 1995; 39:221-6.
  • 5. Sivapalasingam S., Steigbigel N.H. Macrolides, clinda­mycin, and ketolides. In: G.L. Mandell, J.E. Bennett, R. Dolin, ed. Principles & Practice of Infectious Diseases. Churchill Livingstone, 6th edition, 2004, p. 396-417.
  • 6. Lefevre J.C., Escaffe M.C., Courdil M., et al. In vitro evaluation of activities of azithromycin, clarithromycin and sparfloxacin against Chlamidia trachomatis. Phatol Biol 1993; 41:313-5.
  • 7. Renaudin H., Bebear C. Comparative in vitro activity of azithromycin, clarithromycin, erythromycin and lomefloxacin against Mycoplasma pneumoniae, Mycoplasma hominis and Ureaplasma urealyticum. Eur J Clin Microbiol Infect Dis 1990; 9:838-41.
  • 8. Leclercq R. Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications. Clin Infect Dis 2002; 34:482-92.
  • 9. Kamimiya S., Weisblum B. Induction of ermCV by 16memberedring macrolide antibiotics. Antimicrob Agents Chemother 1997; 41:530-4.
  • 10. Carbon C.J., Rubinstein E.. Macrolides, ketolides, lincosamides and streptogramins. In: J. Cohen, W.G. Pow­derly, S.M. Opal, S.F. Berkley, T. Calandra, N. Clumeck, e.a., editors. Infectious Diseases. Elsevier Limited, 2nd edition, 2004, p. 1791-803.
  • 11. Heilmann K., Beekmann S., Richter S., et al. Antimicrobial resistance with Streptococcus pneumoniae in 2003 – results of the Multinational GRASP Surveillance Program. Proceedings of 14th ECCMID, Prague, Czech Republic 2004. Abstr. P1130.
  • 12. Козлов Р.С., Сивая О.В., Шпынёв К.В. Антибиотикорезистентность Streptococcus pneumoniae в России в 1999-2005 гг.: результаты многоцентровых проспективных исследований ПеГАС-I и ПеГАС-II. Clinical Microbiology and Antimicrobial Chemotherapy.2006; 8:33-47.
  • 13. Козлов Р.С., Сивая О.В., Шпынёв К.В. Антибиотикорезистентность Streptococcus pyogenes в России: результаты многоцентрового проспективного исследования ПеГАС-I. Clinical Microbiology and Antimicrobial Chemotherapy.2005; 7:154-66.
  • 14. Culic O., Erakovich V., Pamham M.J. Anti-inflammatory effects of macrolide antibiotics. Eur J Pharmacol 2001; 429:209-29.
  • 15. Mandell G.L. Delivery of antibiotics by phagocytes. Clin Infect Dis 1994; 19:922-5.
  • 16. Tamaoki J. The effects of macrolides on inflammatory cells. Chest 2004; 125:41-51.
  • 17. Foulds G., Shepard R.M., Johnson R.B. The pharmacokinetics of azithromycin in human serum and tissues. J Antimicrob Chemother 1990; 25 (Suppl. A):73-82.
  • 18. Dunn C.J., Barradell L.B. Azithromycin: a review of its pharmacological properties and use as 3-day therapy in respiratory tract infections. Drugs 1996; 51:483-505.
  • 19. Bergan T. Pharmacokinetics of newer macrolides. In: New Macrolides, Azalides, and Streptogramins in Clinical Practice. Neu H.C., Young L.S., Zinner S.H., Acar J.F. (Eds.). New York, etc., 1995: 51-60.
  • 20. Schentag J.J., Ballow C.H. Tissue-directed pharmacokinetics. Am J Med 1991; 91 (Suppl 3A):5-11.
  • 21. Mandell G.L., Coleman E. Uptake, transport, and delivery of antimicrobial agents by human polymorphonuclear neutrophils. Antimicrob Agents Chemother 2001; 45:1794-8.
  • 22. Gialdroni Grassi G., Grassi C. Clinical application of macrolides and azalides in Legionella, Mycoplasma, and Chlamydia respiratory infections. In: New Macrolides, Azalides, and Streptogramins in Clinical Practice. Neu H.C., Young L.S., Zinner S.H., Acar J.F., eds. New York 1995.p.147-54.
  • 23. Yshiguro M., Koga H., Konno S., et al. Penetration of macrolides into human polymorphonuclear leucocytes. J Antimicrob Chemother 1989; 24:719-29.
  • 24. Girard D., Finegan S.M., Dunne M.W., Lame M.E. Enchanced efficacy of single-dose versus multi-dose azithro­mycin regimens in preclinical infection models. J Antimicrob Chemother 2005; 56:365-71.
  • 25. Breen J.D., Zervos M.J., Jorgensen D., Goodrich J.M. Single-dose azithromycin microspheres versus levofloxacin for the treatment of acute exacerbations of chronic bronchitis (AECB). Proceedings of 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 2005 Dec 16-19; Washington
  • 26. Drusano G.L., Craig W.A. Relevance of pharmacokinetics and pharmacodynamics in the selection of antibiotics for respiratory tract infections. J Chemother 1997; 9(Suppl. 3):38-44.
  • 27. Craig W.A. The hidden impact of antibacterial resistance in respiratory tract infections. Re-evaluating current antibiotic therapy. Respir Med 2001; 95 (Suppl.A):12-9.
  • 28. Hopkins S. Clinical toleration and safety of azithromycin in adults and children. Rev Contemp Pharmacother 1994; 5:383-9.
  • 29. Pfizer. Data on file. 2003.
  • 30. Zervos M., Breen J.D., Jorgensen D.M., Good­rich J.M. Novel, single-dose microsphere formulation of azitromycin versus levofloxacin for the treatment of acute exacerbation of chronic bronchitis. Infect Dis Clin Pract 2005; 13:115-21.
  • 31. D’Ignazio J., Camere M. A., Lewis D.E., et al. Novel, single-dose microsphere formulation of azithromycin versus 7-day levofloxacin therapy for treatment of mild to moderate community-acquired pneumonia in adults. Antimicrob Agents Chemother 2005; 49:4035-41.
  • 32. Drehobl M.A., Salvo M.C., Lewis D.E., Breen J.D. Single-dose azitromycin microspheres vs clarithromycin extended release for the treatment of mild-to-moderate community acquired pneumonia in adults. Chest 2005; 128:2230-7.
Views
0 Abstract
0 PDF
0 Crossref citations
Shared